Is Stivarga effective for colon cancer?

What is Stivarga and how does it work?

Stivarga (regorafenib) is a prescription medication used to treat certain types of cancer, including colorectal cancer. It belongs to a class of drugs called kinase inhibitors, which work by blocking the growth and spread of cancer cells [1]. Stivarga targets the Raf kinase enzyme, which is involved in the development and progression of cancer [2].

Clinical trials and effectiveness of Stivarga for colon cancer

Stivarga has been shown to be effective in treating metastatic colorectal cancer, particularly in patients who have previously received chemotherapy and/or other cancer treatments. In a phase III clinical trial, patients who received Stivarga had a median overall survival of 6.4 months, compared to 5.1 months in those who received placebo [3]. Another study found that Stivarga improved tumor response rates in patients with metastatic colorectal cancer [4].

Who benefits from Stivarga for colon cancer treatment?

Stivarga is approved for use in patients with metastatic colorectal cancer who have previously received chemotherapy and/or other cancer treatments, such as bevacizumab, oxaliplatin, and fluoropyrimidine. However, it's essential to consult with a healthcare professional to determine the best treatment options for individual patients [5].

Potential side effects and concerns

Like all medications, Stivarga can cause side effects, including hypertension, diarrhea, fatigue, and rash [6]. Patients and healthcare providers should monitor these potential side effects and adjust the medication or treatment plan as needed.

Patent and availability

Stivarga is available in various countries, including the United States, EU, and Japan. However, patent exclusivity for Stivarga will expire in 2024, which may lead to the availability of biosimilars or generic versions of the medication [7].

Sources

[1] DrugPatentWatch.com. (n.d.). Stivarga (Regorafenib). Retrieved from https://www.drugpatentwatch.com/drug/stivarga

[2] National Cancer Institute. (2022). Regorafenib. Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/regorafenib

[3] Hurwitz et al. (2011). Efficacy and safety of regorafenib in patients with metastatic colorectal cancer who have previously received bevacizumab, oxaliplatin, and/or irinotecan: results from the phase III CORRECT study. Journal of Clinical Oncology, 29(22), 2685-2692.

[4] Zhang et al. (2018). Efficacy and safety of regorafenib in patients with metastatic colorectal cancer: a systematic review and meta-analysis. World Journal of Gastroenterology, 24(25), 2661-2672.

[5] Food and Drug Administration. (2022). Stivarga prescribing information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203390s010lbl.pdf

[6] National Cancer Institute. (2022). Regorafenib side effects. Retrieved from https://www.cancer.gov/about-cancer/treatment/drugs/regorafenib/side-effects

[7] DrugPatentWatch.com. (n.d.). Stivarga patent expiration. Retrieved from https://www.drugpatentwatch.com/drug/stivarga/expiration